‘One, Two, Three Rabies Free’ has also been started to promote the vaccine. Rabies is predicted to kill 59,000 animal bite victims worldwide annually, primarily in Asia and Africa. India alone accounts for more than 20,000 animal bite deaths, as the majority of animal bite victims do not receive the entire course of available vaccines.
ThRabis is a vaccine developed utilizing Virus-Like Particle technology (VLP). The VLPs self-assemble from this recombinant G protein, which is produced from genes cloned into baculovirus expression vectors and expressed in Spodoptera frugiperda (Sf9) insect cells. The vaccination induces antibody production against the rabies G protein, which results in virus neutralization and also blocks virus attachment to the cell, providing protection against rabies.
The ‘Cadila Against Rabies’ event in Ahmedabad drew prominent experts from the Association for the Prevention and Control of Rabies in India (APCRI), including Founder President and Mentor Dr MK Sudarshan; President Dr DH Ashwath Narayana; Secretary General Dr Sumit Poddar; and Treasurer Dr HS Ravish. Cadila Pharmaceuticals Limited (www.cadilapharma.com) is one of India’s leading private pharmaceutical firms. Cadila Pharmaceuticals has spent the last seven decades developing and producing affordable medications and making them available to patients worldwide.
Dr. Rajiv Modi, CMD, Cadila Pharmaceuticals, expressed hopes over the new vaccine. He said, “With this three-dose innovative vaccine, many more lives will be saved – lives that continue to be lost to a preventable disease like Rabies. This vaccine can be a game-changer in our global flight to eliminate rabies through a simpler and more convenient regimen. Continuing our journey of making affordable innovations available to the last man in society, ThRabis® is one more addition to our portfolio of indigenous innovations”.
